Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
BOSTON & OSAKA, Japan--(BUSINESS WIRE)--Jun 23, 2025--
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Ono Pharmaceutical Co., Ltd. (OTCMKTS: OPHLY) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex's povetacicept in Japan and South Korea. Povetacicept is a recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines with best-in-class potential being studied for the treatment of immunoglobulin A nephropathy (IgAN), primary membranous nephropathy (pMN) and other B cell-mediated diseases.
Under the terms of the agreement, Vertex will receive an upfront payment, as well as certain regulatory and commercial milestone payments and tiered royalties. Ono will utilize its extensive development expertise to help advance Vertex's clinical trials for povetacicept and will be responsible for obtaining marketing authorizations in Japan and South Korea. Following approval, Ono will be solely responsible for commercializing povetacicept in these regions. The agreement includes povetacicept for both IgAN and pMN, with the potential to add other indications.
'Ono is a proven leader in Japan and South Korea, bringing established local relationships, infrastructure and nephrology expertise that make them a perfect partner for Vertex as we look to deliver povetacicept to the thousands of potential patients in these countries,' said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. 'We are very pleased to partner with Ono and look forward to close collaboration as we continue to advance this potentially best-in-class treatment for IgAN, pMN and other serious B cell-mediated diseases.'
'Vertex has a strong track record of developing innovative therapies for serious diseases. Through this strategic partnership, we can strengthen our late-stage pipeline in the immunology field, which is a key focus area for Ono,' said Toichi Takino, Representative Director, President and Chief Operating Officer of Ono. 'We look forward to collaborating with Vertex to provide this new therapeutic option for patients with IgAN and other autoimmune diseases in Japan and South Korea, and to maximize the value of this treatment.'
About Povetacicept
Povetacicept is a recombinant fusion protein therapeutic and a dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, which play key roles in pathogenesis of multiple autoimmune diseases via their roles in the activation, differentiation and/or survival of B cells, T cells and innate immune cells. Based upon an engineered TACI (transmembrane activator and calcium modulator ligand interactor) domain, povetacicept has higher binding affinity and greater potency in preclinical studies versus other inhibitors of BAFF and/or APRIL alone and has demonstrated potential best-in-class efficacy in a clinical trial in patients with IgA nephropathy and primary membranous nephropathy. Povetacicept is also in development for multiple serious B cell-mediated diseases including other autoimmune kidney diseases and autoimmune cytopenias.
About IgA Nephropathy (IgAN)
IgAN is a serious, progressive, life-threatening, B cell-mediated chronic kidney disease that is the most common cause of primary (idiopathic) glomerulonephritis, affecting approximately 300,000 people in the United States and Europe. It is estimated that there are approximately 33,000 diagnosed patients in Japan. IgAN results from deposition of circulating immune complexes consisting of immunoglobulins and galactose-deficient immunoglobulin A (Gd-IgA1) in the renal glomerular mesangium, triggering kidney injury and fibrosis. Up to 72% of adult IgAN patients progress to end-stage renal disease within 20 years. There are no approved therapies that specifically target the underlying cause of IgAN.
About Primary Membranous Nephropathy (pMN)
Primary membranous nephropathy is a serious, progressive, life-threatening B cell-mediated chronic kidney disease affecting people worldwide, with approximately 150,000 people diagnosed in the U.S. and Europe. It is estimated that there are approximately 6,000 diagnosed patients with pMN in Japan. pMN is a rare glomerular disease that occurs when the body generates an abnormal immune response, including autoantibodies, against proteins that are part of the kidney. Autoantibodies trigger damage and inflammation, especially within the glomeruli (the parts of the kidney that filter blood), impairing the kidneys' ability to properly filter waste and fluid, eventually causing progressive loss of kidney function. There are no approved therapies that specifically target the underlying cause of pMN.
About RAINIER
RAINIER is a global Phase 3 pivotal trial of povetacicept 80 mg vs. placebo on top of standard of care in approximately 480 people with IgAN. The study is designed to have a pre-planned interim analysis evaluating urine protein to creatinine ratio (UPCR) for the povetacicept arm versus placebo after a certain number of patients reach 36 weeks of treatment. If positive, the interim analysis may serve as the basis for Vertex to seek accelerated approval in the U.S. Final analysis will occur at two years of treatment, with a primary endpoint of total eGFR slope through Week 104.
The Phase 3 clinical trial is underway in multiple regions, including the U.S., EU and Asia. Specifically, Japanese and South Korean regulatory authorities have approved the Clinical Trial Application (CTA) for RAINIER, where the Phase 3 trial is underway.
About RUBY-3
RUBY-3 is an ongoing, multiple ascending dose, multi-cohort, open label, Phase 1/2 basket study of povetacicept in autoimmune glomerulonephritis, including IgAN, primary membranous nephropathy, lupus nephritis and ANCA-associated vasculitis with glomerulonephritis where povetacicept is being administered subcutaneously for up to 104 weeks.
About Vertex
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1.
Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on LinkedIn, Facebook, Instagram, YouTube and X.
About Ono Pharmaceutical Co., Ltd
Ono Pharmaceutical Co., Ltd. delivers innovative therapies for patients worldwide. Upholding its philosophy of 'Dedicated to the Fight against Disease and Pain,' Ono targets areas with unmet medical needs including oncology, immunology, and neurology, and fosters partnerships with academic and biotech organizations to accelerate drug discovery. Through its affiliate, Deciphera Pharmaceuticals, Ono is accelerating clinical development and commercial operations in the US and Europe to drive global business expansion and further its commitment to patient care. For more information, please visit the company's website at https://www.ono-pharma.com/en.
Vertex Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements by Reshma Kewalramani M.D., and Toichi Takino, in this press release, and statements about the terms of and expectations for Vertex's collaboration with Ono, statements about potential benefits and results that may be achieved through the collaboration, statements regarding the future activities of the parties pursuant to the collaboration, including Ono's help to advance clinical trials and Ono's responsibility to obtain marketing authorizations in Japan and South Korea and to commercialize povetacicept in the regions, statements regarding upfront and milestone payments, and potential royalties on future products, and statements about Vertex's plans and expectations for the RAINIER and RUBY-3 clinical trials and potential plans to seek accelerated approval in the U.S. based on interim analysis from the RAINIER trial. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that the anticipated benefits and potential of the collaboration between Vertex and Ono may not be achieved on the anticipated timeline, or at all, that data may not support further development of the therapies subject to the collaboration due to safety, efficacy, or other reasons, and other risks listed under the heading 'Risk Factors' in Vertex's annual report filed with the Securities and Exchange Commission (SEC) and available through Vertex's website at www.vrtx.com and on the SEC's website at www.sec.gov. You should not place undue reliance on these statements. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.
(VRTX-GEN)
Ono Forward-Looking Statements
In this press release, statements made with respect to current plans, estimates, strategies and beliefs, and other statements that are not historical facts are forward-looking statements about the future performance of the company. These statements are based on current assumptions and beliefs in light of the information currently available and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in the business environment in the pharmaceutical market and amendments to relevant laws and regulations, (ii) disruptions to product supply due to stagnation or delays in production caused by natural disasters, fires, etc., (iii) the possibility that sales activities for new and existing products may not achieve the expected results, (iv) the emergence of new side effects in post-marketing drugs, and (v) infringements of intellectual property rights by third parties. Information about pharmaceutical products included in this press release is not intended to constitute an advertisement or medical advice.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250623239210/en/
CONTACT: Vertex Pharmaceuticals Incorporated
Investors:
[email protected]
Media:
[email protected]
or
International: +44 20 3204 5275
or
U.S.: 617-341-6992
or
Heather Nichols: +1 617-839-3607
Ono Pharmaceutical Co., Ltd.
Corporate Communications
[email protected]
KEYWORD: NORTH AMERICA UNITED STATES SOUTH KOREA ASIA PACIFIC JAPAN MASSACHUSETTS
INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH GENETICS PHARMACEUTICAL CLINICAL TRIALS
SOURCE: Vertex Pharmaceuticals Incorporated
Copyright Business Wire 2025.
PUB: 06/23/2025 04:00 AM/DISC: 06/23/2025 04:02 AM
http://www.businesswire.com/news/home/20250623239210/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Health Line
33 minutes ago
- Health Line
10 Health Benefits of Mango
In some parts of the world, mango (Mangifera indica) is called the 'king of fruits'. It's a drupe, or stone fruit, which means that it has a large seed in the middle. Mango is native to India and Southeast Asia, and people have cultivated it for over 4,000 years. Hundreds of types of mango exist, each with its own characteristic taste, shape, size, and color. Mango is not only delicious but also boasts an impressive nutritional profile. Here are 10 benefits of mango, including an overview of its nutritional content and some tips on how to enjoy it. 1. Packed with nutrients Many people love mango — not only because it's delicious but also because it's very nutritious. One cup (165 grams) of fresh mango provides: Calories: 99 Protein: 1.4 grams Carbs: 24.8 grams Fat: 0.6 grams Fiber: 2.6 grams Sugar: 22.6 grams Vitamin C: 67% of the Daily Value (DV) Copper: 20% of the DV Folate: 18% of the DV Vitamin B6: 15% of the DV Vitamin A: 10% of the DV Vitamin E: 10% of the DV Vitamin K: 6% of the DV Niacin: 7% of the DV Potassium: 6% of the DV Riboflavin: 5% of the DV Magnesium: 4% of the DV Thiamine: 4% of the DV One of its most impressive nutrient facts is that just 1 cup (165 grams) of fresh mango provides nearly 67% of the DV for vitamin C. This water-soluble vitamin aids your immune system, helps your body absorb iron, and promotes cell growth and repair. Mango is also a good source of the minerals copper and folate, which are especially important nutrients during pregnancy, as they support healthy fetal growth and development. 2. Low in calories Another benefit of mango is that it's low in calories. One cup (165 grams) of fresh mango contains fewer than 100 calories and has a very low calorie density, meaning that it has few calories for the volume of food it provides. In fact, most fresh fruits and vegetables tend to have a low calorie density. One study found that consuming fresh fruit like mango at the start of a meal could help keep you from overeating later on in the meal. Still, keep in mind this may not be the case for dried mango. Just 1 cup (160 grams)of dried mango contains 510 calories, 106 grams of sugar, and a higher calorie density. Though dried mango is still rich in nutrients like vitamins, minerals, and antioxidants, it may be best to consume it in moderation due to its high calorie density and sugar content. 3. May help prevent diabetes Fresh mango is relatively high in natural sugar compared with other fresh fruits, containing over 22 grams per cup (165 grams). You might think this could be worrisome for people living with metabolic conditions like diabetes, or for those who are trying to limit their sugar intake. Not much research has examined the specific relationship between fresh mango and diabetes. A 2020 study concluded that consuming fruits and vegetables high in vitamin C and carotenoids could help prevent the onset of diabetes. Mango is high in both these nutrients, so it may provide similar benefits, though more research is necessary. Still, because mango is high in natural sugars, it has the potential to cause a spike in your blood sugar levels if you eat too much at one time. Thus, it may still be best to consume mango in moderation, meaning a typical portion size of about 1 cup (165 grams) at a time. It may also help to pair it with other foods that are rich in fiber and protein, as this may help limit blood sugar spikes. 4. High in healthy plant compounds Mango is packed with polyphenols, which are plant compounds that act as antioxidants to protect your body. This fruit has over a dozen different types concentrated in its flesh, peel, and even seed kernel. These include: mangiferin catechins anthocyanins gallic acid kaempferol rhamnetin hydroxybenzoic acid Antioxidants are important because they protect your cells against free radicals. Research has linked free radical damage to signs of aging and chronic diseases. 5. Contains immune-boosting nutrients Mango is a good source of immune-boosting nutrients. One cup (165 grams) of mango provides 10% of your daily vitamin A needs. Vitamin A is essential for a healthy immune system. Plus, 1 cup (165 grams) mango provides nearly 67% of your daily vitamin C needs. This vitamin can help your body produce more disease-fighting white blood cells, help these cells work more effectively, and improve your skin's defenses. Mango also contains other nutrients that may also support immunity, including: copper folate vitamin E several B vitamins 6. Supports heart health Mango contains nutrients that support a healthy heart. For instance, it offers magnesium and potassium, which help maintain a healthy blood flow. These nutrients help your blood vessels relax, promoting lower blood pressure levels. Studies have found that mangiferin may protect heart cells against inflammation, oxidative stress, and cancer. In addition, it may help lower your blood levels of cholesterol, triglycerides, and free fatty acids. While these findings are promising, research on mangiferin and heart health in humans is currently lacking. Therefore, more studies are needed. 7. May improve digestive health Mango has several qualities that make it excellent for digestive health. For one, it contains a group of digestive enzymes called amylases. Digestive enzymes break down large food molecules so that your body can absorb them easily. Moreover, since mango contains plenty of water and dietary fiber, it may help with digestive issues like constipation and diarrhea. One 4-week study in adults with chronic constipation found that eating mango daily was more effective at relieving symptoms of the condition than taking a supplement containing an amount of soluble fiber similar to that of mango. This suggests that mangoes may have other components that aid digestive health, aside from dietary fiber. However, more research is needed. 8. May support eye health Mango is full of nutrients that help support healthy eyes. Two key nutrients they contain are the antioxidants lutein and zeaxanthin. Mangoes are also a good source of vitamin A, which supports eye health. 9. May help lower your risk of certain cancers Mango is high in polyphenols, which may have anticancer properties. Polyphenols can help protect against a harmful process called oxidative stress. Test-tube and animal studies have observed that mango polyphenols reduced oxidative stress. They've also been found to destroy or stop the growth of various cancer cells, such as those in breast cancer. While these studies are promising, more studies in humans are needed to better understand the potential anticancer effects of mango polyphenols in people. 10. Versatile and easy to add to your diet Mango is delicious, versatile, and easy to add to your diet. However, you might find it difficult to cut due to its tough skin and large pit. Here's one good method for cutting a mango: With the mango skin still on, cut long vertical slices 1/4 inch (6 mm) away from the middle to separate the flesh from the pit. Cut the flesh on each of these slices into a grid-like pattern without cutting the skin. Scoop the cut flesh out of the skin. Here are some ways you can enjoy mango: Add it to smoothies. Dice it and mix it into salsa. Toss it into a summer salad. Slice it and serve it along with other tropical fruits. Dice it and add it to quinoa salad. Add mango to Greek yogurt or oatmeal. Top burgers or seafood with grilled mango. Keep in mind that mango is sweeter and contains more sugar than many other fruits. Moderation is key — it's best to limit mango to about 2 cups (330 grams) per day.
CNET
an hour ago
- CNET
Samsung's Cheaper Galaxy Flip 7 FE Foldable Phone Shows Up In New Leak
New renders of the rumored Galaxy Z Flip7 FE phone, a cheaper alternative to last year's Z Flip 6, have hit the internet via notable leaker Evan Blass. The images were shared Monday on smartphone news site Phone Arena. The FE stands for Founders Edition and is Samsung's way of offering comparable devices with slightly weakened specs for more affordable prices. Past FE phones include the Samsung Galaxy S24 FE and the Galaxy Tab S10 FE and FE Plus. The renders show off a device that looks very similar to the Galaxy Z Flip 6, appearing in white and black colorways. Phone Arena reports that the Flip 6 FE will have similar hardware as last year's Flip 6 but may swap out the Snapdragon chip for a Samsung-made Exynos processor. Blass also sharedf renders of the flagship Galaxy Z Flip 7 which, if accurate, will drop the camera cutaway and feature the screen running edge-to-edge, with cutouts for the cameras, much like the Motorola Razr Ultra 2025. Foldable phones, once $2,000 devices, have slowly started creeping downwards in price as designs have improved and more players have entered the space. Despite more foldable phones entering the market, it's still a smaller piece of the overall larger smartphone pie. Trendforce predicted last year that 17.8 million foldables would ship in 2024, making up only 1.5% of overall smartphone shipments. Foldable phone shipments actually decreased 1%, making it the segment's first-ever Q3 decline, according to Counterpoint Research. That decline was attributed to weak performance from the Samsung's Z Flip 6, which was a mild improvement over 2023's model. While Samsung is the foldable market global leader at 56% share, the Z Flip and Fold 6 saw shipments fall 21%. With more exciting handsets coming out of China, where Samsung has a smaller presence, consumers might be holding out for either cheaper prices or more exciting designs. Already, rumors claim that Apple might be readying its own foldable device, which may expand the market as well as pull share from Samsung. There are other concerns with foldables, apart from the higher price point. According to a 2023 Kantar report, 55% of early foldable buyers later switched back to a regular slab phone. Lower battery life and software uncertainty is what drove people away, according to the report. A 2024 YouGov report said 56% of young adults said durability was a major concern when considering a foldable. Some foldable phones are seeing more affordable price points, notably, the new Motorola Razr 2025, which has a starting price of $700. If the rumored Z Flip 7 FE can match or undercut Motorola, that could entice some consumers.
Motor 1
2 hours ago
- Motor 1
Toyota's Prices Are Going Up
In the market for a new Toyota? Better get to the dealership soon. Toyota will begin hiking prices for its vehicles by an average of $270 beginning in July. According to Automotive News , these latest price increases aren't in response to President Trump's 25-percent tariff on imported vehicles and auto parts. A company spokesperson said it's simply "part of our regular review of the prices." Lexus buyers won't be off the hook for additional costs, either. Prices for Toyota's luxury brand are expected to increase by an average of $208 beginning in July. Toyota & Tariffs Even though the company denies that these latest price hikes are in response to tariffs, in May, Toyota Motor North America Chief Operating Officer Mark Templin said that President Trump's plan would result in higher prices and more expensive repair bills. Templin stated: 'When it comes to tariffs on auto parts, it's important to understand the supply chains are global, they're complex, and they're very fragile. And many of the suppliers are not capitalized for an abrupt tariff. So levies on parts will negatively impact the automobile supply chain and lead to higher prices, lower vehicle sales, and will make servicing and repairing vehicles more expensive for customers.' That said, a report from Reuters suggests that Toyota is considering moving production of the newest RAV4 to the US, rather than importing from Canada and Japan. Toyota produced the outgoing RAV4 in Kentucky, Canada, and Japan, but could keep production of the next-generation model in Kentucky. The Toyota RAV4 was the best-selling SUV in the US last year and the fourth best-selling vehicle overall, with more than 475,000 units sold. Car Prices Are Going Up Toyota isn't the only automaker expected to raise prices this year. BMW has announced that it will start hiking prices in July in response to Trump's tariffs, with some models increasing by as much as $2,500. BMW did offer a temporary "price protect" program for the 2 Series and 3 Series models through April. Volkswagen also plans to increase prices in July after announcing pre-tariff pricing through June. The Jetta sedan and Taos SUV, which are both produced in Mexico, are expected to be hit hardest by price increases next month. Other brands like Ford, Subaru, and Volvo have already raised prices on their vehicles—some models by as much as $2,000. More on Tariffs Car Shipments to the US Have Fallen. Guess Why Volvo CEO: Customers Must Pay Tariff Costs, Not Us Get the best news, reviews, columns, and more delivered straight to your inbox, daily. back Sign up For more information, read our Privacy Policy and Terms of Use . Source: Automotive News Share this Story Facebook X LinkedIn Flipboard Reddit WhatsApp E-Mail Got a tip for us? Email: tips@ Join the conversation ( )
